Onconova Therapeutics initiates phase 1/2a study of rigosertib plus nivolumab to treat KRAS+ lung adenocarcinoma

Press/Media

Period	24 Jun 2020

Media coverage

Title	Onconova Therapeutics initiates phase 1/2a study of rigosertib plus nivolumab to treat KRAS+ lung adenocarcinoma
Media name/outlet	PharmaBiz
Country/Territory	India
Date	24/06/20
URL	www.pharmabiz.com/NewsDetails.aspx?aid=129076&sid=2
Persons	Rajwanth Veluswamy